The Recall Desk
SevereFDA (Drugs)·D-0223-2025·Announced 2025-02-12

Adrenalin Chloride Epinephrine Nasal Solution Recalled for Misleading Label

Par Pharmaceutical is recalling Adrenalin Chloride Solution (Epinephrine Nasal Solution) due to a misleading label that resembles the FDA-approved Adrenalin epinephrine injection product, creating potential confusion.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: FDA Class I classification requires minimum severity of 4. Although no illnesses or injuries have been reported, the misleading labeling of an epinephrine product creates a real risk of medication confusion with serious health consequences possible.

Plain-English summary

ENDO USA, Inc., distributed by Par Pharmaceutical, is recalling Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP) 30mg/30mL (1mg/mL) packaged in 30 mL amber glass vials. The recall affects 44,397 vials and includes all lots currently within expiry.

The product's label is misleading and similar in appearance to the FDA-approved Adrenalin (epinephrine injection, USP) product. This labeling issue creates a risk of product confusion between the nasal solution formulation and the injection formulation.

The product was distributed nationwide throughout the United States. This is a Class I recall issued by the FDA.

The recalled product

Product
Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP), 30mg/30mL (1mg/mL), packaged in 30 mL vials, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-103-01
Manufacturer
ENDO USA, Inc.
Category
Drug
Hazard
  • label-confusion

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots within expiry

Distribution

Distributed nationwide across the United States.